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Abstract Given the multiple differences between mice and
men, it was once thought that mice could not be used to
model atherosclerosis, principally a human disease. Apolipo-
protein E-deficient (apoEKO) mice have convincingly changed
this view, and the ability to model human-like plaques in these
mice has provided scientists a platform to study multiple facets
of atherogenesis and to explore potential therapeutic inter-
ventions. In addition to its well-established role in lipopro-
tein metabolism, recent observations of reduced adiposity
and improved glucose homeostasis in apoEKO mice sug-
gest that apoE may also play a key role in energy metabo-
lism in peripheral organs, including adipose tissue. Finally,
along with apoEKO mice, knockin mice expressing human
apoE isoforms in place of endogenous mouse apoE have
provided insights into how quantitative and qualitative ge-
netic alterations interact with the environment in the patho-
genesis of complex human diseases.—Pendse, A. A., J. M.
Arbones-Mainar, L. A. Johnson, M. K. Altenburg, and N.
Maeda. Apolipoprotein E knock-out and knock-in mice: ath-
erosclerosis, metabolic syndrome, and beyond. J. Lipid Res.
2009. S178–S182.
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Apolipoprotein E (apoE) plays a central role in lipopro-
tein metabolism and is required for the efficient clearance
of diet-derived chylomicrons and liver-derived VLDL rem-
nants by the liver (1). Consequently, mice lacking apoE
(apoEKO) provided the first practical model of hyperlip-
idemia and atherosclerosis. In this review, we revisit the
primary features of lipoprotein metabolism and athero-
sclerosis in apoEKO mice and the contributions of human
apoE isoforms using the apoE knock-in mice. We then
extend our discussion to more recent observations that
suggest an important role for apoE in peripheral energy
metabolism and consequently in metabolic syndrome
(MetS) and its components, mainly obesity and diabetes.
LIPOPROTEIN METABOLISM IN APOEKO MICE
Plasma cholesterol in wild-type mice on a regular chow
diet is ?80 mg/dl, primarily carried in HDL particles.
Mice have a small amount of LDL and other atherogenic
lipoproteins, such as VLDL remnants. This high HDL-to-
LDL ratio is maintained even when mice are fed diets
similar to those consumed by humans in Western society.
This is in marked contrast with humans who carry the
majority of their plasma cholesterol in LDL (110 mg/dl)
(2). It is well established in humans that a low ratio of
HDL to LDL cholesterol confers a high risk of atheroscle-
rosis and subsequent cardiovascular disease (3). Thus, the
natural atheroprotective lipoprotein profile in mice could
account for the absence of these pathologic conditions.
Despite the different plasma lipid profiles, cholesterol
transport and metabolism are sufficiently similar in the
two species, suggesting that inducing suitable disturbances
in plasma lipoprotein metabolism would also lead to ath-
erosclerosis in mice. Gene targeting in embryonic stem
cells developed during the 1980s (4–6) opened the door
to test this concept, and mice homozygous for a defective
apoE gene were produced by us and independently by
Plump et al. in 1992 (7–9).
Although extremely rare, humans lacking apoE are re-
ported to have elevated remnant cholesterol in plasma
(10). Similar to these individuals, apoEKO mice accumu-
late cholesterol-rich remnant particles with plasma choles-
terol levels reaching 400 mg/dl, even when fed a regular
low-fat, low-cholesterol diet.
ATHEROSCLEROSIS IN APOEKO MICE
Although atherosclerosis is not a distinguishing feature
described in apoE-deficient humans (10), apoE deficiency
alone proved to be sufficient for aortic atherosclerotic
plaques to develop in mice. In addition, diets high in
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fat and cholesterol markedly accelerate plaque develop-
ment in these mice. Thus, apoEKOmice, and subsequently
mice lacking the LDL receptor (LDLR) that develop severe
atherosclerosis on a Western-type diet (11), have demon-
strated that hyperlipidemia is an essential prerequisite for
the development of atherosclerotic lesions.
The lesion development and plaque composition in
apoEKO mice is also similar to that in humans, establish-
ing it as an excellent animal model for studying the patho-
genesis of atherosclerosis. A small collection of foam cells
that are tightly adhered to the aortic valve begin to appear
in mice at about 2 months of age. With time the complex-
ity of the lesion increases to have fibrous caps, a necrotic
core of foam cell debris, cholesterol crystals, and calcifica-
tions. Large advanced plaques are often associated with
the thickening of medial and adventitial tissue, accompa-
nied by chronic inflammation. Lesions with spontaneous
hemorrhage and rupture, the features associated with clini-
cal symptoms of human atherosclerosis, have been ob-
served in some studies of older, cholesterol-fed mice (12,
13). However, the occurrence of these events in apoEKO
mice is not sufficiently reliable, leaving room for improve-
ment in studying the plaque rupture process.
ApoEKO mice have been used extensively for several
years to study the impact of various genetic and environ-
mental risk factors on atherosclerotic susceptibility and re-
sistance and to evaluate the effects of various therapeutic
means. These studies have been comprehensively reviewed
elsewhere (14).
MICE WITH HUMAN APOE ISOFORMS
While the apoEKO mouse has been established as an
excellent model of atherosclerosis, the lack of apoE is
extremely rare in the human population. However, apoE is
polymorphic in humans, and plasma LDL cholesterol levels
and atherosclerosis risk are both strongly associated with
the three common apoE isoforms in the order of apoE4 .
apoE3 . apoE2. This association is rather counterintuitive
because apoE4 (Arg-112 and Arg-158) binds to LDLR with a
slightly higher affinity than apoE3 (Cys-112 and Arg-158),
while apoE2 (Cys-112 and Cys-158) binds to the receptor with
much reduced affinity (15).
Unlike in humans, the plasma lipoprotein profiles in
apoE knockin mice expressing the human apoE proteins in
place of mouse apoE are reflective of their different LDLR
affinities. Thus, mice with apoE3 and apoE4 are normo-
lipidemic and do not develop atherosclerosis even on a
Western-type diet (15). In contrast, mice with human apoE2,
which binds to LDLR with less affinity, accumulate plasma
remnants with high cholesterol and triglycerides (TG) and
develop atherosclerosis (16).
Surprisingly, however, mice with human apoE2, E3, or
E4 recapitulate the lipoprotein profiles of their human
counterparts when they also express a high amount of
the human LDLR and are fed a Western-type diet (17).
Thus, an increased expression of LDLR in mice with hu-
man apoE4 causes an accumulation of cholesterol-rich,
apoE-poor remnants in plasma, a reduction of HDL, and
severe atherosclerosis. In marked contrast, the same in-
crease in LDLR in apoE2 mice ameliorates their hyper-
lipidemia and diet-induced atherosclerosis. These results
raise the possibility that apoE4, by binding strongly to ex-
cess LDLR, is prevented from transferring to nascent lipo-
proteins, a step necessary for their subsequent clearance.
This in turn leads to an increase in the plasma concentra-
tion of apoE-poor remnants. Indeed, we found that pri-
mary hepatocytes from apoE4 mice secrete less apoE into
the medium than hepatocytes from apoE2 mice. Increased
LDLR expression leads to a localization of apoE4 on the
hepatocyte surface and enhances sequestration of apoE-
deficient VLDL remnants injected into apoE4 mice. How-
ever, these surface-bound VLDL were poorly internalized
compared with apoE2 mice (18).
ApoE isoform-dependent changes in cholesterol uptake
and efflux from macrophages have been reported (19, 20).
Cholesterol delivery to macrophages in culture increases
as LDLR expression increases, and the effect was more
prominent in apoE4 macrophages than those with apoE3
(21). Conversely, increased LDLR expression reduces cho-
lesterol efflux from macrophages expressing apoE4 but
not apoE3 (22). Consequently, in mice with human apoE4
that lack the LDLR (LDLRKO), the replacement of bone
marrow cells with cells expressing LDLR increased athero-
sclerosis in a dose-dependent manner compared with mice
transplanted with LDLRKO cells. In contrast, atherosclero-
sis in LDLRKO mice expressing human apoE3 was not
affected by the bone marrow with varying levels of LDLR
expression (22). Although further tests are required to ex-
trapolate these findings in mice to humans, interactions
between apoE isoforms and LDLR in macrophages likely
contribute to the association of apoE4 with an increased
cardiovascular risk in humans.
APOEKO MICE AND ADIPOSE TISSUE BIOLOGY
In addition to its primary site of synthesis in the liver,
apoE is also synthesized in peripheral tissues, including
adipose tissue (23, 24). Recent studies indicate that apoE
may be a crucial player in peripheral lipid uptake and
energy homeostasis and consequently in the development
of MetS. MetS is a combination of several conditions, includ-
ing obesity, hyperglycemia, hyperinsulinemia, dyslipidemia,
hypertension, and a prothrombotic, proinflammatory state
(25). Obesity is a prominent aspect of MetS, and adipose
tissue is now considered to be an important regulator of
energy metabolism. Expression of apoE in adipocytes de-
creases in response to obesity and tumor necrosis factor-a
but increases with fasting and weight loss (26, 27). ApoE ex-
pression is regulated by nuclear receptors, such as liver X
receptor and peroxisome proliferator-activated receptor g
(PPARg), which is vital for adipocyte differentiation (28).
ApoEKO mice are leaner than wild-type mice (29–31).
Absence of apoE also reduces body weight and some of
their obesity-associated metabolic complications, including
impaired glucose tolerance and insulin resistance in obese
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models, such as ob/ob and Ay/1 mice (30, 32, 33). Im-
paired delivery of liver-derived VLDL to adipocytes could
partly account for the suppressed body weight gain and
fat accumulation in apoEKO mice. In the adipocyte, apoE
interacts with the VLDL receptor, which facilitates hydro-
lysis of TG by LPL (34). Indeed, mice lacking the VLDL
receptor are protected from obesity (35). Chiba et al. (30)
showed that wild-type VLDL, but not VLDL from apoEKO
mice, induces differentiation of bone marrow stromal cells
and 3T3-L1 cells into adipocytes. However, LPL inhibition
did not alter the adipogenic activity of VLDL, suggesting
that apoE-mediated VLDL uptake, but not hydrolysis of
VLDL, plays a major role in adipogenesis.
Modulation of adiposity and tissue insulin sensitivity by
adipose-derived apoE is suggested by the work of Huang
et al. (36), who showed that apoE synthesized by adipocytes
promotes TG uptake in culture and that the lack of endog-
enous apoE led to a marked defect in TG uptake from ex-
ogenous VLDL even when the VLDL contained apoE. The
uptake was restored by adenoviral expression of apoE. The
authors further showed that a PPARg agonist increased
apoE expression and TG accumulation in wild-type adipo-
cytes, but the same PPARg stimulation produced signifi-
cantly less TG synthesis and TG accumulation in apoEKO
adipocytes. Thus, adipose-derived apoE may play a role in
intracellular lipid storage in an autocrine and/or paracrine
fashion. Further studies are necessary to determine the rela-
tive roles of lipoprotein-associated, circulating apoE and
apoE synthesized by adipose tissue in metabolic homeostasis.
HUMAN APOE ISOFORMS AND ADIPOSITY
Epidemiological studies have suggested that the apoE
polymorphism modifies a long recognized association be-
tween increased body fat, particularly abdominal fat, and
increased plasma VLDL in humans (37). For example, in
the Heritage Family Study population, a pleiotropic quan-
titative trait locus for TG and adiposity was found on
ch19q13 where APOE is located (38). ApoE isoforms were
associated with body mass index in the order of apoE4 ,
apoE3 , apoE2 in 15,000 individuals from the Athero-
sclerosis Risk in Communities study (39).
Similar to their human counterparts, mice expressing
human apoE3 gain more body weight and adipose tissue
mass than mice with apoE4 when fed a Western-type diet.
Despite being leaner, apoE4 mice begin to show impair-
ment of glucose tolerance earlier than apoE3 mice, mainly
because adipocytes expressing apoE4 fail to buffer post-
prandial lipids and glucose completely (40). Adenoviral ex-
pression of apoE3 in cultured apoE-null adipocytes induced
mRNA expression for adiponectin in a dose-dependent man-
ner, but the induction was significantly blunted in cells ex-
pressing apoE4. ApoE4 expression increased mRNA for
Glut1, but not Glut4, in adipocytes, suggesting that apoE4
may be interfering with insulin-regulated pathways. These
apoE isoform-dependent effects on body fat are a reminder
that in addition to total fat mass, the functionality of fat cells
is also an important determinant of disease risk.
APOE IN DIABETES AND BEYOND
Cardiovascular incidents as a consequence of athero-
sclerosis are significantly increased in diabetic patients.
Multiple diabetic atherosclerosis studies have employed
apoEKO mice to induce diabetes with streptozotocin in-
jection, which ablates the insulin producing b-cells in the
pancreas. The resulting type 1 diabetes accelerated ath-
erosclerosis development in apoEKO mice in association
Fig. 1. ApoE-mediated TG uptake by liver and adipose tissue contributes to maintaining normal plasma lipid levels (left panel). Impaired
TG uptake in liver and adipose tissue in the absence of apoE contributes to the accumulation of VLDL and chylomicron remnants in the
plasma and foam cell accumulation in the vessel wall (right panel). The arrows represent changes in lipid accumulation in different tissues
in the presence and absence of apoE. ApoE is important in peripheral energy metabolism and may have an effect on plaques in addition to
its established role in lipoprotein trafficking.
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with an increase in plasma cholesterol levels (41). How-
ever, the diabetes-induced enhancement of atherosclero-
sis is attenuated, without a significant change in plasma
lipid levels, by the administration of the soluble receptor
for advanced glycation end products (42), rosiglitazone
(43), or lipoic acid (44), among others. Thus, the increased
oxidative stress and inflammation consequent to the high
plasma glucose are major contributors to accelerated ath-
erosclerosis in diabetes.
Type 2 diabetes is more common than type 1 diabetes
in humans. In contrast with the consistently observed
increase in atherosclerosis by the streptozotocin-induced
type 1 diabetes, data are conflicting regarding the effects of
type 2 diabetes on atherosclerosis development in apoEKO
mice. For example, insulin resistance due to the lack of the
insulin receptor substrate 2 gene was shown to accelerate
atherosclerosis development in apoEKOmice (45). By con-
trast, a reduction of atherosclerosis has been reported in
apoEKO mice treated with gold thioglucose to destroy the
hypothalamic satiety center and to produce type 2 diabetes
(46). Similarly, while leptin receptor deficiency (db/db) in-
duces key features of type 2 diabetes in apoEKO mice, in-
cluding hyperglycemia, hyperinsulinemia, dyslipidemia,
and accelerated atherosclerosis (47), deficiency in the lep-
tin receptor protects LDLRKO mice from atherosclerosis
(48). Conflicting results have been reported in apoEKO
mice with leptin deficiency (ob/ob): an increased athero-
sclerosis in chow-fed mice by Gruen et al. (49) and smaller
plaques in mice fed an atherogenic diet by Chiba et al.
(50). While different experimental conditions, such as
diet and methods employed for atherosclerosis evalua-
tion, may be contributing to these different outcomes,
reconciliation of these differences is of great interest be-
cause hyperleptinemia and insulin resistance frequently
occur together in MetS patients.
Figure 1 illustrates the metabolic roles of apoE in vivo.
ApoE-mediated lipoprotein uptake in liver and adipose tis-
sue lowers plasma lipids (left panel). By contrast, impaired
lipoprotein uptake by the liver, in the absence of apoE,
leads to an increase in VLDL and chylomicron remnants
in the plasma and increased formation of foam cells in
the vessel wall and atherosclerosis (right panel). On the
other hand, apoE deficiency also reduces adiposity and
improves insulin sensitivity, which may have an atheropro-
tective potential. In the studies of diabetic atherosclerosis,
such as those described above, apoEKO mice have provided
an effective sensitizer for atherosclerosis, but the possibility
that apoE may also have direct roles in the pathogenesis of
diabetes and its complications has not been addressed. The
potential roles of apoE isoforms in MetS and the develop-
ment and progression of diabetic complications highlight
the future use of the apoE knockin mice in elucidating the
mechanisms by which apoE exerts isoform-specific effects.
Our understanding of apoE in energy metabolism be-
yond its role in lipoprotein metabolism is still far from
complete. The impairments in metabolic disorders have a
potential to modulate atherosclerosis and cardiovascular
disease progression. Similar to their contributions toward
the understanding of lipoprotein metabolism and patho-
genesis of atherosclerosis, apoEKO mice and mice with
humanized apoE will be invaluable in elucidating these
roles in future studies.
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